A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis
This study is testing a new injectable medicine called survodutide to see if it can improve liver health in adults with a serious fatty liver disease called MASH. Researchers want to find out if this medicine can help heal liver scarring and stop the disease from getting worse.
You may be able to join if you are 18 or older, have stable liver scarring due to MASH, and meet specific body weight (BMI) requirements. People with heavy alcohol use or severe liver complications cannot take part.
You will take either the study medicine or a placebo as a weekly injection under your skin, along with healthy lifestyle counseling. The study lasts for up to four and a half years with regular check-ins, health tests, and questionnaires.
This study is currently recruiting participants and has locations in cities across Arizona, United States. Visits will happen at the study site or via video call.
- 1Testing an investigational weekly injection called survodutide for fatty liver disease
- 2Includes guidance on healthy diet and regular exercise for all participants
- 3Long-term study lasting up to four and a half years with regular health check-ups
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.